J&J Targets $100B+ Sales in 2026 as Growth Accelerates in Both Units [Yahoo! Finance]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Yahoo! Finance
J&J said it expects sales in the range of $100.0 billion-$101.0 billion in 2026. This range was slightly higher than the then Zacks Consensus Estimate of $98.5 billion. Adjusted earnings per share are expected to be in the range of $11.43-$11.63. J&J expects accelerated growth in both the Innovative Medicine and MedTech segments in 2026. In 2025, Innovative Medicine Unit's sales rose 4.1% on an operational basis to $60.4 billion. In 2026, J&J expects accelerated growth in the Innovative Medicine segment despite the loss of exclusivity (“LOE”) of blockbuster drug, Stelara. Several biosimilar versions of J&J's multi-billion-dollar immunology drug, Stelara, were launched in the United States in 2025 as the drug lost patent exclusivity. According to patent settlements and license agreements, Amgen AMGN , Teva Pharmaceutical Industries TEVA, Samsung Bioepis/Sandoz and some other companies launched Stelara biosimilars in 2025. Stelara's LOE negatively impacted the Innovative Medicine
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- UBS Raises Amgen (AMGN) Target as Pharma and Biotech Setup Improves [Yahoo! Finance]Yahoo! Finance
- Steve Jobs' son says he can help end cancer deaths - and he's raising millions to do it [Yahoo! Finance]Yahoo! Finance
- Amgen (NASDAQ:AMGN) was given a new $400.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have an "outperform" rating on the stock.MarketBeat
- AMGEN ANNOUNCES WEBCAST OF 2025 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTSPR Newswire
- Amgen Set to Report Q4 Earnings: What Investors Should Know [Yahoo! Finance]Yahoo! Finance
AMGN
Earnings
- 11/4/25 - Beat
AMGN
Sec Filings
- 1/30/26 - Form 8-K
- 11/21/25 - Form 4
- 11/20/25 - Form 144
- AMGN's page on the SEC website